Despite overall higher earnings in its three business segments combined, healthcare giant Mallinckrodt saw a decline in year over year sales and revenues within its imaging division during the first quarter of 2000 (end-September). The St. Louis-based
Despite overall higher earnings in its three business segments combined, healthcare giant Mallinckrodt saw a decline in year over year sales and revenues within its imaging division during the first quarter of 2000 (end-September). The St. Louis-based company reported total sales of $614 million for the quarter, a 4% increase over sales of $592 million for the same quarter a year ago. Net earnings for the quarter were $38 million, up 19% from first quarter 1999 earnings of $32 million. Mallinckrodt chairman and CEO C. Ray Holman attributed the improvement in profitability to stronger sales of its pulse oximetry, radiopharmaceutical, and pharmaceutical products.
However, Mallinckrodts imaging group reported a 1% decrease in year over year revenues for the quarter, due primarily to lower sales of its x-ray contrast media and diagnostic catheter products. The imaging division recorded $182 million in sales, compared to $184 million for the first quarter of 1999. Quarterly earnings for the division fell 24% to $23 million from earnings of $31 million for the same quarter a year ago.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.